Biology subjects

Rocha, F. E. O.

Publications and source records attributed to Rocha, F. E. O..

3 recordsLinked to original sources

bioRxiv2025

P2Y12-P-Selectin Mediated Platelet Activation Drives Dengue-Associated Thrombocytopenia

Dengue virus (DENV) infection frequently causes thrombocytopenia, a hallmark of severe disease. The underlying mechanisms of this condition remain incompletely understood. Using a murine model that mirrors human hematologic and inflammatory responses, we show that DENV impairs megakaryopoiesis, causing necrotic loss of bone marrow megakaryocytes and compensatory thrombopoietin elevation. Megakaryocyte-derived platelets exhibit mitochondrial dysfunction and phosphatidylserine exposure, consistent with apoptosis. Systemically, DENV drives P-selectin- dependent platelet activation and platelet-monocyte aggregates, accompanied by increased plasmatic chemokines (CXCL4, CCL5, CXCL1) and vascular leakage in target organs such as liver and lungs, reflecting heightened thromboinflammation. Pharmacologic blockade of P-selectin or inhibition of P2Y12 with clopidogrel restored platelet counts, rescued megakaryocyte numbers, and reduced systemic inflammation. Collectively, these findings demonstrate for the first time in an in vivo model that DENV-induced thrombocytopenia arises from combined megakaryocyte impairment and platelet hyperactivation and highlight platelet-targeted interventions as potential therapeutic strategies. KEY POINTSO_LIDENV disrupts platelet production and survival via megakaryocyte necrosis and intramedullary platelet apoptosis, driving thrombocytopenia. C_LIO_LIDENV triggers thrombocytopenia via P-selectin platelet activation; blocking it with antibody P-selectin or clopidogrel reduces inflammation. C_LI

immunology↗

bioRxiv2025

Cyclodextrin-Based Delivery of the Annexin A1 Mimetic Peptide Ac2-26 Enhances Anti-Inflammatory Effects and PreventsDengue-Induced Lethality in Combination with AntiviralTherapy

Severe dengue is characterized by systemic inflammation, cytokine storm, vascular leakage, and hemorrhagic manifestations, largely driven by the host immune response to dengue virus (DENV) infection. Despite its burden, no licensed antivirals or host-directed therapies are currently available. Our group has previously identified Annexin A1 (AnxA1) as an endogenous regulator of inflammation in dengue. Treatment with the AnxA1 peptidomimetic, Ac2-26, improved clinical outcomes in murine models of severe dengue by promoting resolution of inflammation without affecting viral control. To explore new delivery strategies, we developed a novel formulation of Ac2-26 complexed with hydroxypropyl-{beta}-cyclodextrin (CDX-Ac2-26). In DENV-2-infected A129 mice, both intraperitoneal and oral CDX-Ac2-26 improved clinical scores and reversed thrombocytopenia. Notably, CDX-Ac2-26 reduced mast cell degranulation, MCPT-1 plasma levels, and CCL2 expression in spleen, with no effect on viral titers, indicating a host-targeted mechanism and overcoming the anti-inflammatory effects of the free peptide. Intraperitoneal administration achieved the same efficacy as oral dosing with only one-third of the dose. Importantly, the combination of CDX-Ac2-26 with the antiviral nucleotide analog sofosbuvir fully prevented disease and mortality in infected mice, highlighting a combinatorial effect between host-directed and antiviral therapies. These findings underscore the therapeutic potential of anti-inflammatory/pro-resolving strategies in severe dengue and support the development of CDX-Ac2-26 as a novel adjunctive treatment. Combining anti-inflammatory and antiviral approaches may enhance efficacy and reduce treatment-associated toxicity, offering a promising path for clinical translation. What is already known on this topic?O_LIPlasma levels of Annexin A1 are inversely correlated with the severity of clinical outcomes in dengue virus infection. C_LIO_LIThe Annexin A1 peptidomimetic Ac2-26 exhibits anti-inflammatory and pro-resolving effects against severe dengue in a murine model. C_LI What does this study add?O_LIThe Ac2-26-cyclodextrin complex enhances the anti-inflammatory effects of the peptide against dengue virus infection, allowing for lower dosing and oral administration. C_LIO_LIThe administration of the CDX-Ac2-26 with a nucleoside analog antiviral exhibits a combinatorial effectt, providing complete protection against the lethal outcome of severe dengue. C_LI What is the clinical significance?O_LICurrent dengue treatment relies on symptomatic management, as no directed anti-inflammatory agents or antivirals are currently available. We have identified a novel host-targeted strategy to resolve the disease. C_LIO_LIOur findings strongly support CDX-Ac2-26 as a promising adjunctive treatment strategy in combination with antiviral therapy for severe dengue, highlighting the potential of combinatorial approaches. C_LI

immunology↗

bioRxiv2024

PI3Kγ pathway contributes to neuroinflammation and neuronal death induced by Zika virus infection

Zika virus (ZIKV) is an emerging arbovirus belonging to the Flaviviridae family and Orthoflavivirus genus, with a pronounced tropism for the central nervous system (CNS), where it induces neuroinflammation and neuronal death. ZIKV is known to exploit host cellular mechanisms, including the activation of survival pathways such as the PI3K/AKT signaling cascade, to evade apoptosis and enhance its replication. The phosphatidylinositol 3-kinase {gamma} (PI3K{gamma}) pathway regulates critical cellular processes, including differentiation, recruitment, and survival, and is abundantly expressed in both brain tissue and leukocytes. This study aimed to investigate the role of the PI3K{gamma} pathway during ZIKV infection. Primary neuronal cultures from PI3K{gamma}-deficient mice (PI3K{gamma}kd/kd) and human neuroblastoma SH-SY5Y cells treated with the PI3K{gamma} inhibitor AS605240 were infected with ZIKV to assess the impact of PI3K{gamma} signaling on viral replication and neuronal survival. Additionally, interferon /{beta} receptor knockout (A129) mice were treated with AS605240 either before or after ZIKV infection to evaluate the pathways role in neuroinflammation. In vitro, both genetic ablation and pharmacological inhibition of PI3K{gamma} suppressed ZIKV replication and prevented neuronal death. In vivo, mice treated with the PI3K{gamma} inhibitor exhibited enhanced protection against ZIKV infection, characterized by reduced viral load, and diminished brain and optic nerve damage. This neuroprotective effect correlated with altered astrocyte and microglia activation, marked by reduced TNF production in microglia. Furthermore, inhibition of PI3K{gamma} curtailed the recruitment and activation of CD8+ T cells and decreased the production of pro-inflammatory mediators, including IFN-{gamma} and IL-17, in the brains of ZIKV-infected mice. These findings suggest that PI3K{gamma} activation facilitates ZIKV infection and exacerbates neuroinflammation. Pharmacological inhibition of the PI3K{gamma} pathway may offer therapeutic benefits by limiting viral replication and alleviating neuroinflammatory responses during ZIKV infection.

immunology↗